ABOUT EVENT
About
So, What's New for 2025?
CEO Think Tank
Kicking off our first day of the summit, the CEO and global leaders from the field’s leading mRNA-dedicated biotechs will share their personal thoughts on the current state-of-play, pipeline strategy and decision-making to set the mRNA roadmap into 2025.
- Alexander Zehnder, Chief Executive Officer, CureVac
- Bo Ying, Chief Executive Officer, Abogen Biosciences
- Ansgar Santel, Chief Executive Officer, Pantherna Therapeutics
- Jenny van Asbeck - van der Wijst, Chief Executive Officer, Mercurna
- Pierre Wils, Global Scientific Advisory Lead - mRNA Centre of Excellence, Sanofi
- Nigel Horscroft, Chief Technology Officer, Stealth Mode mRNA Biotech
Hear the latest mRNA-dedicated proof-of-concept in vivo model strategies to combat extrahepatic targeting, new therapeutic areas from obesity to cardiac and autoimmune diseases and vaccine areas including CMV, Influenza
and Gonorrhea to fight emerging health threats.
KEY PRE-CLINICAL DEVELOPMENT UPDATES
mRNA TECHNOLOGY & INNOVATION DAY
Unlock your mRNA development toolbox with design optimization, carrier formulations, extra-hepatic applications and gene editing tools to ensure you are up to date with the hottest on-going research in the mRNA field with insights from leading academia and industry players.
Providing the ultimate global platform to showcase new and emerging platform technologies, 2025 brings you an all-star line-up of new biotech entrants from across Europe and Asia ready to unlock the power of mRNA and transform revolutionary mRNA-based treatments for patients faster.
BRAND NEW COMPANIES FOR 2025
Key Sessions for 2025:
Unlocking European specific regulatory guidance on mRNA platform designation and licensing of personalised medicine towards successful approval with MHRA and Swiss Medic
Overcoming tolerability and translatability from preclinical models to IND with new entrants including CureMed Biotechnology and NeoVacs
Key clinical progress updates with in-human trials towards clinical safety and validation with CureVac, Ethris and Abogen Biosciences
Brand New mRNA Technology & Innovation day, focused on novel non-viral delivery formulations, gene editing, and process advancements to give you the ultimate mRNA development toolbox
Streamlining mRNA CMC and manufacturing to achieve global equity at low cost and increased production capacity and supply with Afrigen Bio and Sinergium Biotech
Keeping up the momentum into 2025 with mRNA partnerships and collaborations across Europe with new research initiatives including REGeRNA, BAXERNA and EXPERT projects
Divide and Conquer:
The mRNA R&D pipeline is vast, which is why we have meticulously researched with subject matter experts and key industry leaders to identify the key challenges facing the community, from senior scientists, to directors, to C-Level executives… the problems are different, but together we can tackle them.
By splitting into 2 tracks; Discovery & Pre-Clinical Development and Clinical Development & Manufacturing, our speakers will be tailoring their presentations to hone on specific challenges for those stages of development.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned.
A snapshot of the key sessions in each track:
TRACK A
TRACK B
Advancing mRNA Therapeutics: A New Frontier in the Treatment of Obesity & Metabolic Disease
Xiangrong Song, Co-Founder & General Manager, WestGene Pharma
Development of mRNA Vaccine Candidates for Pandemic Influenza
German Sanchez Alberti, Development & Innovation Manager, Sinergium Biotech
Uncovering Key Critical Safety Requirements for Clinical & Post-Authorisation Measures for mRNA Vaccines & Therapeutics
Marie Caby-Tosi, European Economic Area/ United Kingdom Qualified Person for Pharmacovigilance, Moderna
Techno-Economic Modelling for Sustainable, Low Cost & Scalable mRNA Medicines Manufacturing for LMICs
Zoltán Kis, Associate Professor – Department of Chemical & Biological Engineering, University of Sheffield